Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
<< View all publications

Special Issues

Folate Receptor Alpha as a Therapeutic Target for Ovarian Cancer
Folate Receptor Alpha as a Therapeutic Target for Ovarian Cancer
The Role of Folate Receptor Alpha in the Treatment of Ovarian Cancer   >   Articles
Moore Assesses Potential Impact of Antibody-Drug Conjugates in Ovarian Cancer Treatment
Moore Assesses Potential Impact of Antibody-Drug Conjugates in Ovarian Cancer Treatment
The Role of Folate Receptor Alpha in the Treatment of Ovarian Cancer   >   Articles
Birrer Shares Perspective on Folate Receptor Alpha-Targeting Agents in Ovarian Cancer
Birrer Shares Perspective on Folate Receptor Alpha-Targeting Agents in Ovarian Cancer
The Role of Folate Receptor Alpha in the Treatment of Ovarian Cancer   >   Articles
Evaluating the Role of Folate Receptor Alpha Expression in Ovarian Cancer
Evaluating the Role of Folate Receptor Alpha Expression in Ovarian Cancer
The Role of Folate Receptor Alpha in the Treatment of Ovarian Cancer   >   Articles
Targeting BCL-2 in Hematologic Malignancies
Targeting BCL-2 in Hematologic Malignancies
Focus on Pathways: Inhibition of the BCL-2 Pathway in Hematologic Malignancies   >   Articles
BCL-2: Mechanisms and Prevalence
BCL-2: Mechanisms and Prevalence
Focus on Pathways: Inhibition of the BCL-2 Pathway in Hematologic Malignancies   >   Articles
Erdafitinib Shows Promise in FGFR-Aberrant Cholangiocarcinoma
Erdafitinib Shows Promise in FGFR-Aberrant Cholangiocarcinoma
FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress   >   Articles
Pemigatinib Emerging as Potential Second-Line Treatment for Cholangiocarcinoma
Pemigatinib Emerging as Potential Second-Line Treatment for Cholangiocarcinoma
FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress   >   Articles
Cholangiocarcinoma Emerges as Key Target of FGFR Inhibitor Research
Cholangiocarcinoma Emerges as Key Target of FGFR Inhibitor Research
FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress   >   Articles
Infigratinib Active in Intrahepatic Cholangiocarcinoma
Infigratinib Active in Intrahepatic Cholangiocarcinoma
FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress   >   Articles
Next Page >>
Publication Bottom Border
Border Publication
 
x